|
[Related PubMed/MEDLINE]
Total Number of Papers: 20
|
|
|
|
|
[Display Entries]
|
| |
|
[Entries Per Page]
|
|
per page
|
| |
|
Page Control
|
|
|
|
Page: of
|
|
|
|
| Abbreviation |
: PsAID |
| Long Form |
: Psoriatic Arthritis Impact of Disease |
|
| No. |
Year |
Title |
Co-occurring Abbreviation |
| 1 |
2020 |
Assessment of the Patient Acceptable Symptom State (PASS) in psoriatic arthritis: association with disease activity and quality of life indices. |
DAPSA, MDA, PASS, PsA, VLDA |
| 2 |
2020 |
Construct validity of the ASAS health index in psoriatic arthritis: a cross-sectional analysis. |
ASAS-HI, AUC, DAPSA, PsA |
| 3 |
2020 |
Disease Activity in Psoriatic Arthritis Index and Psoriatic Arthritis Impact of Disease Questionnaire: correlation and sensitivity to change in a real clinical setting. |
DAPSA, PsA, SMR |
| 4 |
2020 |
Disease features associated with a low disease impact in patients with psoriatic arthritis: results of a cross-sectional multicenter study. |
DIP, HAQ, MDA, PsA |
| 5 |
2020 |
Impact of Comorbidities on Disease Activity, Patient Global Assessment, and Function in Psoriatic Arthritis: A Cross-Sectional Study. |
DAPSA, FM, HAQ-DI, MDA, PsA, PtGA, SCC |
| 6 |
2020 |
Mismatch between the impact of disease perceived by patients and the state of clinical remission assessed by physicians in psoriatic arthritis. |
DAPSA, DAPSA, PASS, PsA |
| 7 |
2020 |
Results of a global, patient-based survey assessing the impact of psoriatic arthritis discussed in the context of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire. |
HRQoL, PsA |
| 8 |
2020 |
Validation and clinical interpretability of PsAID - psoriatic arthritis impact of disease. |
CASPAR, EULAR, ICC, PsA |
| 9 |
2019 |
A novel role for the psoriatic arthritis impact of disease (PsAID) questionnaire. |
cDAPSA, HAQ, LDA, MDA, REM |
| 10 |
2019 |
Determinants of Patient-Reported Psoriatic Arthritis Impact of Disease: An Analysis of the Association With Sex in 458 Patients From Fourteen Countries. |
DAPSA, MDA, NRS, OR, PsA |
| 11 |
2019 |
Effect of filgotinib on health-related quality of life in active psoriatic arthritis: a randomized phase 2 trial (EQUATOR). |
HRQoL, MCII, PASS |
| 12 |
2019 |
Measuring Outcomes in Psoriatic Arthritis: Comparing Routine Assessment of Patient Index Data and Psoriatic Arthritis Impact of Disease. |
PARC, PRO, PsA, RAPID3 |
| 13 |
2019 |
Very Low Disease Activity, DAPSA Remission, and Impact of Disease in a Spanish Population with Psoriatic Arthritis. |
CASPAR, DAPSA, VLDA |
| 14 |
2018 |
Achieving international consensus on the assessment of psoriatic arthritis in psoriasis clinical trials: an International Dermatology Outcome Measures (IDEOM) initiative. |
COSMIN, IDEOM, PG, PsA, RAPID, RCT |
| 15 |
2018 |
Content and Face Validity and Feasibility of 5 Candidate Instruments for Psoriatic Arthritis Randomized Controlled Trials: The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Annual Meeting. |
FACIT, GRAPPA, HAQ-DI, PsA, SPARCC |
| 16 |
2018 |
Minimal Disease Activity and Patient-Acceptable Symptom State in Psoriatic Arthritis: A Real-World Evidence Study With Ustekinumab. |
MDA, OR, PsA, UST |
| 17 |
2017 |
Validation of the Psoriatic Arthritis Impact of Disease (PsAID) Questionnaire and its potential as a single-item outcome measure in clinical practice. |
ICC, PROM, PsA, SRM |
| 18 |
2015 |
Patient global assessment in psoriatic arthritis - what does it mean? An analysis of 223patients from the Psoriatic arthritis impact of disease (PsAID) study. |
--- |
| 19 |
2015 |
Patient participation as an integral part of patient-reported outcomes development ensures the representation of the patient voice: a case study from the field of rheumatology. |
EULAR, PROs |
| 20 |
2014 |
A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. |
NRS, PsA |
|
A Search Service for Abbreviation / Long Form
